7,625.48

+45.41

+0.60%

52,282.48

+512.17

+0.99%

25,643.71

+206.71

+0.81%

2,829.29

+17.45

+0.62%

4.8900

-0.0390

-0.79%

18.97

-0.45

-2.32%

3,971.80

+72.90

+1.87%

77,624.42

-300.23

-0.39%

Crude Oil Dec 26

97.27

-6.85

-6.58%

US Private Equity

10,850.63

-82.20

-0.75%

NasdaqCM - Nasdaq Real Time Price USD

Edesa Biotech, Inc. (EDSA)

2.5003 -0.0697 (-2.69%)

As of 9:37:35 AM EST. Market Open.

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Edesa Biotech Announces FDA IND Clearance for Phase 2 Vitiligo Study

GlobeNewswire 18d ago

EDSA
-2.69%
EDSA: Recruitment in Phase 2 Vitiligo Study Set to Get Underway

Zacks Small Cap Research 2mo ago

EDSA
-2.69%
Edesa Biotech Announces Proposed Public Offering

GlobeNewswire 2mo ago

EDSA
-2.69%
Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results

GlobeNewswire 2mo ago

EDSA
-2.69%
EDSA: Positive Exploratory Data in Patients with AKI

Zacks Small Cap Research 3mo ago

EDSA
-2.69%
Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors

GlobeNewswire 4mo ago

EDSA
-2.69%
Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury

GlobeNewswire 4mo ago

EDSA
-2.69%
EDSA: Preparing for Mid-2026 Start to Phase 2 Vitiligo Trial

Zacks Small Cap Research 5mo ago

EDSA
-2.69%
EDSA: Preparing for Mid-2026 Start to Phase 2 Vitiligo Trial

Zacks Small Cap Research 5mo ago

EDSA
-2.69%
Edesa Biotech Reports Fiscal 2nd Quarter 2026 Results

GlobeNewswire 5mo ago

EDSA
-2.69%
Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit

GlobeNewswire 6mo ago

EDSA
-2.69%
EDSA: Gearing Up to Initiate Phase 2 Vitiligo Trial in Mid-2026

Zacks Small Cap Research 10mo ago

EDSA
-2.69%

Performance Overview

Return	EDSA	S&P 500 (^GSPC)
YTD	+80.99%	+10.73%
1-Year	+37.43%	+11.11%
3-Year	-18.41%	+81.91%

Mobilize your Website

View Site in Mobile | Classic

Share by: